Thymosin Beta-4 vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4Anti-Aging & Longevity
Chonluten- Summary
- Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- Not well characterized; likely similar to TB-500 (~1–2 hours)
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- SubQ, IM
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mg
- 10 mg per day
- Frequency
- 2x per week (loading), then 1x per week (maintenance)
- Daily for 10–30 days
- Key Benefits
- Systemic tissue repair and regeneration
- Promotes cardiac recovery after myocardial infarction
- Hair follicle regeneration and anti-hair-loss
- Anti-inflammatory (systemic)
- Wound healing acceleration
- Neuroprotection after brain injury
- Protects against ischemia-reperfusion injury
- Anti-aging at cellular level
- Synergizes powerfully with BPC-157
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Generally very well tolerated
- Injection site reactions
- Mild fatigue at initiation (repair signaling)
- Rare: mild inflammatory response
- +1 more
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —